Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Even on a good day, DNA is constantly getting damaged. Nicks, scratches, breaks: the delicate strands that carry life's genetic code take a beating as they jumble about in the course of their work. If left untreated, errors accumulate, with fatal consequences -- such as cancerous tumors -- for the cell and the organism.
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn's Perelman School of Medicine.
A new study finds breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, which appears in CANCER, states that compared to the general population in the United States, the risk of new cancer diagnoses among survivors was 20% higher for those with hormone receptor (HR) positive cancers and 44% higher for those with HR-negative cancers.
Modified immune cells that ruthlessly kill cancerous tumors may prove a game-changer for people living with late-stage cancer.
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Cancer immunotherapy involves the activation of cells in the patient’s own immune system to fight tumor cells.
Researchers at Mayo Clinic have combined results from a functional test measuring the effect of inherited variants in the BRCA2 breast and ovarian cancer gene with clinical information from women who received genetic testing to determine the clinical importance of many BRCA2 variants of uncertain significance (VUS).
Genetic inheritance affects the likelihood of developing breast cancer. Some genes are already known to increase cancer risk; other genes are suspected to be involved, but not to what extent. It is crucial to clarify this issue to improve prevention since it opens the way to more personalized follow-up and screening programs.
Researchers at Tel Aviv University have demonstrated that the CRISPR/Cas9 system is very effective in treating metastatic cancers.
That carbon nanotubes fluoresce is no longer a surprise. Finding a second level of fluorescence is surprising and potentially useful.
Researchers have shown that the advanced CRISPR/Cas9 system is extremely effective in curing metastatic cancers.
Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project** which aims to dramatically improve the diagnosis and treatment of ovarian cancer.
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumors were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.
High-grade serious ovarian carcinoma is the fifth major cause of cancer-associated deaths in women in the United States.
A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment.
Recent discoveries made by researchers at Texas A&M University could change the way ovarian cancer is understood and treated.
With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells.
In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke.
The cover for issue 29 of Oncotarget features Figure 5, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.
Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more breast and ovarian cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London.